Preferred Label : Autologous Anti-B7-H3 CAR-iC9-expressing T-lymphocytes;
NCIt synonyms : Autologous Anti-B7-H3 CAR-iC9-expressing T-cells; Autologous Anti-B7-H3 CAR-iCasp9-expressing T Cells; Autologous iC9-B7-H3 CAR-T Cells; iC9-CAR.B7-H3 T Cells;
NCIt definition : A preparation of autologous T-lymphocytes that have been genetically modified to express
a chimeric antigen receptor (CAR) specific for the immunoregulatory protein B7-homologue
3 (B7-H3, CD276) and the suicide gene inducible caspase 9 (iCasp9 or iC9), with potential
immunostimulating and antineoplastic activities. Upon administration, autologous anti-B7-H3
CAR-iC9-expressing T-lymphocytes specifically target and bind to B7-H3-expressing
tumor cells, resulting in tumor cell lysis. B7-H3, a type I transmembrane protein
and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain
tumor cell types and on various immune cells. It is a negative regulator of T-cell
activation and its overexpression plays a key role in tumor cell invasion and metastasis.
The iCasp9 safety switch consists of a full-length caspase 9, including its caspase
recruitment domain, linked to a human FK506 drug-binding domain with an F36V mutation
(FKBP12-F36V). If the administered CAR T-cells lead to unacceptable side effects,
the chemical homodimerizer AP1903 can be administered. AP1903 binds to the FKBP12-F36V
drug-binding domain, activates caspase 9 and results in apoptosis of the administered
CAR T-cells.;
NCI Metathesaurus CUI : CL1927377;
Origin ID : C204924;
chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_target
